We explored nonsteroidal anti-inflammatory drug (NSAID) and aspirin (ASA) use and mortality in the U.S. Department of Health and Human Services' registry of 683 adult and 838 pediatric critically ill pandemic 2009 H1N1 influenza (pH1N1) patients. Among adults, 88 (12.9z) and 101 (14.8z) reported pre-admission use of an NSAID and ASA, respectively; mortality was similar (23-24z) regardless of NSAID or ASA use. Mortality among 89 pediatric NSAID users and 749 nonusers did not differ significantly (10.1z and 8.8z, respectively). One of 16 pediatric ASA users died. Among pediatric patients, the adjusted relative risk estimate for NSAID use and 90-day mortality was higher when influenza vaccination was included in the model (risk ratio [RR] ＝ 1.5; 95z confidence interval, 0.7-3.2), although not statistically significant. Among adults, RR estimates did not change appreciably after adjusting for age, sex, health status, or vaccine status. We found no compelling evidence that NSAID or ASA use influenced mortality in severe pH1N1.
SUMMARY:
We explored nonsteroidal anti-inflammatory drug (NSAID) and aspirin (ASA) use and mortality in the U.S. Department of Health and Human Services' registry of 683 adult and 838 pediatric critically ill pandemic 2009 H1N1 influenza (pH1N1) patients. Among adults, 88 (12.9z) and 101 (14.8z) reported pre-admission use of an NSAID and ASA, respectively; mortality was similar (23-24z) regardless of NSAID or ASA use. Mortality among 89 pediatric NSAID users and 749 nonusers did not differ significantly (10.1z and 8.8z, respectively). One of 16 pediatric ASA users died. Among pediatric patients, the adjusted relative risk estimate for NSAID use and 90-day mortality was higher when influenza vaccination was included in the model (risk ratio [RR] ＝ 1.5; 95z confidence interval, 0.7-3.2), although not statistically significant. Among adults, RR estimates did not change appreciably after adjusting for age, sex, health status, or vaccine status. We found no compelling evidence that NSAID or ASA use influenced mortality in severe pH1N1.
Beyond the association of Reye's syndrome with pediatric use of ASA during influenza (1) concerns have been raised about the effects of non-steroidal antiinflammatory drugs (NSAIDs) on the clinical course of influenza (2-4), although some have proposed that NSAIDs could be beneficial (5) .
A retrospective cohort study in Japan suggested that NSAID use, specifically the use of mefenamic acid and diclofenac, was associated with increased mortality from influenza-associated encephalopathy in children (6) . In 184 cases of influenza encephalopathy, the adjusted odds ratios for mortality with acetaminophen, diclofenac, and mefenamic acid were 1.46 (0.38-5.56), 16.34 (1.27-210), and 9.44 (0.70-128), respectively. Japan's Ministry of Health, Labour and Welfare cautioned against pediatric use of diclofenac and mefenamic acid in the treatment of influenza encephalopathy (7) . However, the study has limitations that complicate interpretation of these results, since severity of illness may have influenced NSAID use.
The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response developed a pandemic 2009 H1N1 Influenza (pH1N1) Critical Care Registry (pH1N1 CCR), using the National Heart, Lung, and Blood Institute, National Institutes of Health, research network for Acute Respiratory Distress Syndrome (ARDSNet) (8) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) (9) network. Using the pandemic registry, we sought to evaluate the impact of NSAID use on the clinical course of severe influenza.
The study populations were hospitalized adults and children receiving intensive care for pH1N1 and registered in the pH1N1 CCR between April 15, 2009, and April 15, 2010. Detailed methods for the pH1N1 CCR have been described previously for the adult (10) and pediatric patient cohorts (11) . The use of de-identified data from the pH1N1 CCR was approved by the U.S. Food and Drug Administration's Research in Human Subjects Committee. Patients had confirmed or probable pH1N1 infection. Cases of pH1N1 were confirmed by positive reverse transcriptase-PCR or viral culture, and probable pH1N1 cases were those testing positive for influenza A without further subtyping. Categorical information on exposure to NSAIDs (yes or no) or ASA (yes or no) at home before admission was obtained from medical records and included in the standard data collection for the pH1N1 CCR. Specifically, the case report form noted,``Select all medications that patient was on at home.'' Any diagnosis of encephalitis (determined by magnetic resonance imaging, high cerebrospinal fluid protein, or clinical evaluation) was recorded. Adults were followed up to 60 days and children up to 90 days following intensive care unit admission or until death or hospital discharge.
Mortality was compared between NSAID users and nonusers, and ASA users and nonusers, among adults and children. Univariate analyses were conducted using chi-square and Fisher's exact tests. Multivariate models adjusted for age, sex, and vaccination and health status were evaluated using SAS's PROC GENMOD procedure, which produced risk ratios (RRs) using a generalized linear model. All analyses were completed using SAS version 9.3 software (Cary, NC, USA) (12) .
Among the 683 adult confirmed and probable pH1N1 NSAIDs, Aspirin, pH1N1 Influenza Mortality cases, 12.9z (n ＝ 88) reported NSAID use, and 14.8z (n ＝ 101) reported ASA use, before admission (Table  1) . Only 9 patients reported exposure to both an NSAID and ASA before admission. Adult NSAID users and nonusers had similar distributions regarding sex, race, body mass index (BMI), and influenza antiviral drug use at baseline (Table 1) . Adult NSAID users were more likely than nonusers to have reported an influenza vaccination (29.8z vs. 20.0z) and to have no documented comorbidities (28.6z vs. 18.1z). Adult NSAID users were less likely to have exposure to statins at baseline compared with NSAID nonusers (6.0z vs. 14.0z). Adult ASA users were similar to ASA nonusers with respect to race, BMI, and influenza antiviral drug use at baseline. Adult ASA users were more likely to be men (51.0z vs. 43.5z), to have reported an influenza flu vaccination (30.6z vs. 19.6z), and to have reported statin use at baseline (33.7z vs. 9.4z) compared with adult ASA nonusers. Adult ASA users were also less likely to report no prior comorbid conditions before admission (10.2z vs. 21.0z). Overall, ASA users may have been less healthy than the ASA nonusers, whereas the NSAID users may have been healthier than the NSAID nonusers. NSAID users were younger on average than ASA users (mean age; 42 and 51 years, respectively).
Among 838 pediatric confirmed and probable influenza cases, 10.6z reported exposure to an NSAID, whereas only 1.9z reported exposure to ASA, at home before hospital admission. Table 1 displays the distributions of demographic and clinical factors for pediatric patients by NSAID user and nonuser status. Mortality among adult NSAID or ASA users and nonusers was very similar (22-24z). Among all pediatric patients, mortality was 9.0z. Pediatric NSAID users had a slightly higher rate of mortality compared with pediatric NSAID nonusers (10.1z vs. 8.8z). Only 16 of the pediatric patients used ASA, of whom 1 died, yielding a mortality of 6.3z among ASA users, compared with 9.0z among ASA nonusers (Table 2) .
Neither NSAIDs nor ASA use at home before admission was statistically significantly associated with mortality in the adult or pediatric pH1N1 critical care patients ( Table 2 ). The unadjusted RRs for the associations of NSAID and ASA use with 60-day mortality in adults were 0.9 (95z confidence interval [CI], 0.6-1.4) and 1.0 (95z CI, 0.7-1.4), respectively. Similarly, among children, the RR for the association between NSAID use and 90-day mortality was 1.1 (95z CI, 0.6-2.2). The RR for the association between ASA use 1) 0.9 (0.5-1.6) 1.1 (0.6-1.9) 1.5 (0.7-3.2) Not calculated 1) : Adjusted for age, sex, influenza vaccine status, and whether in good health or not before illness. NSAID, non-steroidal anti-inflammatory drug; ASA, aspirin.
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and 90-day mortality could not be estimated with any meaningful precision owing to the small number of pediatric ASA users. Among adults, RR estimates did not change appreciably after adjusting for age, sex, health status, or vaccine status (data not shown). Among pediatric patients, the RR for the association between NSAID use and 90-day mortality was higher when influenza vaccine was included in the model (RR ＝ 1.5; 95z CI, 0.7-3.2), although still not statistically significant. Further evaluation of the relationship between flu vaccine status and health status revealed that a higher proportion of patients with poor health status (1 comorbidity) received the flu vaccine (30.7z) compared with patients with good health status (17.9z). This suggests that patients with comorbidities were more likely to be vaccinated. However, the elevated RR associating NSAIDs with mortality remained elevated after adjusting for vaccine status, health status and other covariates, albeit without statistical significance.
Mefenamic acid and diclofenac were reported by Nagao et al. to be associated with encephalopathy mortality in pediatric patients hospitalized for seasonal (non-pH1N1) influenza in Japan (6) . Based on that finding, we explored whether NSAID and ASA use before admission to intensive care among patients with pH1N1 influenza was associated with mortality in adults and children. Our results did not support the finding by Nagao et al. We acknowledge several limitations of our analysis. We could not assess possible doseresponse relationships or proximity of NSAID or ASA dose to influenza symptoms, as the specific NSAID product, dose, duration, and timing of administration were unknown. Similarly, we were unable to distinguish between pre-admission use of ASA for cardioprotection versus antipyresis and analgesia in adults, as these indications were unknown. For adults, imbalances in statin use might cause confounding, since statin use has been associated with lower influenza mortality (13); however, in our data, we did not observe such a mortality difference (data not shown) and did not adjust for statin use. Finally, pediatric use of ASA was infrequent, possibly reflecting concerns regarding Reye's syndrome, and our sample of 16 pediatric ASA users was inadequate to assess the risk of mortality from ASA use in the severe influenza pediatric cohort.
There are several possible explanations for our null findings. First, the primary NSAID recommended for influenza in the U.S. is ibuprofen, which may not be associated with risk of mortality in influenza patients. Second, we were not able to analyze encephalopathy mortality, as there were only 14 pediatric encephalitis cases; perhaps the association of NSAIDs with mortality in the setting of influenza is specific to encephalopathy mortality. Third, because we were not able to validate exposures to NSAIDs or ASA with medical records, non-differential misclassification of these exposures is possible and, if present, could bias results toward the null. Finally, our results reflect a sample with very low anti-influenza drug use at baseline and may have differed if more patients had used antiinfluenza drugs in the early stage of illness.
We did not find pre-hospitalization NSAID or ASA use by adults or NSAID use by children admitted for critical care with severe pH1N1 to be associated with risk of mortality. Statistically, the analysis between NSAIDs use and mortality risk was powered to demonstrate a 2-fold risk among adults and a 4-fold risk among children at a 95z confidence level. This level of statistical power should have been adequate for detecting the 16-fold risk of pediatric influenza encephalopathy mortality reported by Nagao et al. (6) . However, because the current study was unable to specifically evaluate encephalopathy mortality, further studies are needed to examine the risk of encephalopathy mortality associated with NSAID use among patients with influenza.
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